Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Inclusion Criteria: * Men and women who are \>/=18 and \</=70 years of age. Female subjects must be of non-childbearing potential. * LDL-C \>/=100 mg/dL who are either not on a lipid-lowering therapy or who are on stable statin therapy. * Body mass index (BMI) \>18 and \<38 kg/m2 * Mild hypertensives on a stable dose of no more than one antihypertensive drug Exclusion Criteria: * History of any prior or concomitant clinical condition or acute and/or unstable systemic disease compromising subject inclusion * Systolic blood pressure \<90 mmHg or \>160 mmHg or diastolic blood pressure \<50 or \>100 mmHg at screening * Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C virus antibody * Abnormal liver function test at Screening (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \>2 × the upper limit of normal \[ULN\] * Estimated glomerular filtration rate \<60 mL/min/1.73 m2 at screening, as determined by the CKD-EPI Equation * History of prescription drug abuse, illicit drug use (including marijuana), or alcohol abuse * Unable to spend 4 days in confinement unit * History of allergy to protein-based biologics including, but not limited to, mAbs and vaccine * Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study